IQVIA Holdings, Inc.
IQV · NYSE
- Prev Close
- $228.20
- Market Cap
- $39.18B
- Open
- —
- Trailing P/E
- —
- Day Range
- $238.22 - $230.44
- 52W Range
- $251.36 - $154.50
- Forward P/E
- —
- EPS
- —
- Volume
- 745.52K
- Dividend Yield
- —
About IQVIA Holdings, Inc.
IQVIA provides proprietary healthcare data, technology, and clinical research services to life-sciences customers. Its business is built around a data platform that helps customers analyze healthcare markets and an expanding clinical research operation that supports drug development and commercialization. The supplied evidence does not quantify the revenue contribution of each activity or identify additional segment percentages. IQVIA generated $16.3 billion of revenue and $1.4 billion of net income in fiscal 2025, compared with $15.4 billion of revenue and $1.4 billion of net income in fiscal 2024, establishing its current scale as a large, profitable healthcare-services and information company.
Notable Price Movement
- Aug 3-7$228.202.90%
IQVIA fell 6.07%, from $242.94 to $228.20, as an initial post-earnings rally reversed. The stock rose 1.9% to $247.56 on July 29, but declined 3.9% on July 30, another 1.2% on July 31, and a further 2.9% across August 3-4. The earlier advance had followed a second-quarter earnings beat, record $3.15 billion bookings, and higher 2026 guidance, but the subsequent retreat suggests investors questioned execution and backlog conversion. Insider selling may also have weighed on sentiment: the CEO disclosed an exercise-and-sell transaction at a $245.51 weighted-average price on July 29, while another insider sold 558 shares at $245.21. No broader market context was supplied.
Stories & Analysis
Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can LastAn IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should KnowAn IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should KnowAn IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion
